Introduction and Background
Antenatal screening programs combined with maternal and infant antiretroviral treatment (ART), planned delivery, and avoidance of breast-feeding have had a dramatic impact on mother-to-child transmission (MTCT) of HIV infection in resource rich settings. 1, 2 Nonetheless, even where there is ready access to such programs, a low level of transmission persists. 3, 4 Efforts must now focus on trying to identify weak points in our current programs that might be targeted in an effort to eradicate residual transmission.
Even in countries with well-developed programs for prevention of mother-to-child transmission (MTCT) of HIV, there remains a low level of ongoing transmission. Pregnant, HIV-infected women may not always access screening and available interventions because of circumstances, beliefs, and other influences. Missed opportunities for the prevention of MTCT remains an issue to be addressed. Through a review of HIV-infected children born during the years of antenatal screening in Ireland, we sought to identify further targets for intervention to further reduce MTCT.
Keywords: HIV; antenatal screening; MTCT; reducing transmission; targets their diagnosis. Prospectively gathered maternal and infant data include maternal demographics, timing of diagnosis, maternal serology, HIV viral load, CD4 counts, pregnancy interventions, infant treatment, and outcome. All HIV-infected children are referred to a single center for management. For this study, data on all infected infants born in the years 1999 to 2005 were abstracted and supplemented by retrospective chart review. A diagnosis of HIV infection was made based on confirmed detection of HIV-RNA by polymerase chain reaction PCR testing (Roche Amplicor) in an infant or HIV antibody detection in a child more than 18 months of age.
Results
Twelve HIV-infected infants were born in Ireland during the study period: 9 to women diagnosed before or during pregnancy and 3 to women diagnosed postnatally.
Infants Born to Women Diagnosed Before or During Pregnancy
In the 7-year period, there were 631 HIV-positive pregnancies in 466 mothers, including 6 twin pregnancies, which resulted in 635 live born infants during this time. In this time period, 165 mothers had 2 to 4 pregnancies; 79% (366) of the mothers were African, of whom 41% were Nigerian, 28% South African, and 31% from various other parts of Africa; 20% (93) were Irish; 2% (7) were of other nationalities, mainly Eastern European. HIV infection was confirmed in 7 female and 2 male infants, all born to African women. Maternal and infant characteristics are listed in Table 1 .
Eight newly diagnosed women had migrated to Ireland while pregnant, 4 at ≤20 weeks and 4 at ≥32 weeks gestation. The mean gestation at diagnosis was 26 weeks. One additional woman (patient 5), aware of her diagnosis preconception, failed to present for care until 37 weeks gestation. Details of treatment, timing of initiation, and duration are listed in Table 1 . Six of nine had ART initiated after 29 weeks gestation. The duration of treatment was less than 6 weeks in 6 women (patients [1] [2] [3] [4] [5] 9) , in 2 of whom (patients 5, 9) there was opportunity for earlier initiation of ART. Problems with medication adherence were recognized in one (patient 6). Refusal to present to hospital at labor onset resulted in prolonged rupture of membranes in 1 case (patient 7). All women received intrapartum zidovudine (ZDV) prophylaxis. No infant had fetal scalp monitoring performed or instrumental delivery. All infants were formula fed and commenced antiretroviral (ARV) prophylaxis within 4 hours of birth to be continued until 4 weeks of age. In 4 infants (infants 4-6, 9), HIV-RNA was detected by PCR testing on day 1 of life, supporting in utero transmission. Three infants (infants 2, 3, 8) were diagnosed on day 42 with earlier negative PCR, suggesting perinatal transmission. However, maternal highly active antiretroviral therapy (HAART) coupled with infant treatment could have resulted in early viral suppression; thus, in utero transmission cannot be reliably excluded. For the 2 remaining infants (infants 1, 7), the first available PCR results were on day 42 and 6 respectively. Late initiation of ARV medications (patients 1-5, 9) and poor adherence to medications (patient 6) or to delivery plan (patient 7) were identified risk factors in this group. There was but 1 infant in whom no identifiable, potentially modifiable risk factors for transmission were found (infant 8).
There were no resistant mutations found in the infected infants. Clade subtyping of mothers yielded 3 subtype C, 3 recombinant forms, and 1 subtype G; sequences could not be obtained for 2 mothers.
Infants Born to Women Diagnosed Postnatally
Three infected infants, 2 female and 1 male, were born to women diagnosed postpartum. One symptomatic formula-fed infant, diagnosed at 6 months of age, was born to an Irish intravenous drug user who had tested HIV negative at 14 and 36 weeks gestation. Testing at delivery was not performed. The second infant was born to an African asylum seeker who arrived in the third trimester, was dispersed to a peripheral town, and delivered at 37 weeks prior to scheduled testing. Testing at delivery was not performed. Breast-feeding was established before maternal testing at 6 weeks postpartum. The third infected infant was born to an African mother who had opted out of antenatal screening in 2003. Two years later, maternal HIV infection was diagnosed when she presented with pulmonary tuberculosis (TB). Subsequent testing confirmed infection in her child.
Discussion
Implementation of antenatal screening programs and active management of HIV-positive pregnant women have dramatically reduced transmission rates from about 25% to 35% to less than 2%. 1 Overall, the program for prevention of MTCT of HIV in Ireland has been similarly successful with a MTCT transmission rate of <1.5% (data not shown). However, this represents 9 infected infants whose mothers were known to be HIV positive in pregnancy.
Audit of the 9 patients detected clearly identifiable risk factors for transmission in 8 women: late initiation of ARV medications in 6 and poor adherence to management recommendations in 2. However, given the current migration patterns 6 and the timing of arrival of pregnant women, often late in pregnancy, missed opportunities for intervention locally were identified in only 4 women (patients [5] [6] [7] 9) . Patient 5, despite knowledge of her status preconception presented only at 37 weeks; patients 6 and 7 did not adhere to management recommendations. Clearly, it is important to seek a better understanding of the reasons why women delay accessing treatment or are nonadherent with recommendations. These failures suggest a lack of understanding of the potential benefits of interventions and indicate a need for continued education of women in this regard. Patient 9, with low-level viremia throughout pregnancy, received less than 6 weeks of ZDV monotherapy. 7 Although Cesarean section delivery is usually recommended for women receiving ZDV monotherapy, 8, 9 it would not have prevented transmission in this case where HIV detection on day 1 of life indicated in utero transmission. Earlier initiation of ZDV or use of HAART might have prevented transmission.
Timing of initiation of ART is clearly critical if MTCT is to be minimized. 10, 11 This is highlighted by the 4 late arrivals to Ireland (patients 1-4) for whom earlier local intervention was not possible. The global roll out of prevention of MTCT programs will hopefully have an impact on this, such that women can readily access treatment in their country of origin prior to migration.
Three infected infants were born to women diagnosed after delivery. Lack of knowledge of HIV infection status in pregnancy and at delivery is potentially the most important and most remediable risk factor for vertical transmission of HIV infection. Women known to be at risk for HIV infection should have repeat testing at delivery to detect those who seroconvert in pregnancy. 12, 13 Indeed, it could be argued that because selective screening programs based on identification of risk groups generally fail, all women could be offered HIV testing at delivery. The use of rapid testing at delivery 14 is a next important step if residual transmission is to be reduced. It would detect those who seroconvert in pregnancy and those who missed earlier testing opportunities. This could have allowed for intervention and potential altered outcome in 2 cases here.
Refusal of antenatal screening often arises because of a lack of understanding of the benefits of testing. It is important, particularly in the context of migrant populations, that good information is easily accessible, that neither language nor cultural differences are barriers to understanding, and that misperceptions of negative repercussions of a positive HIV test are corrected.
There was just 1 case in whom no additional risk factors were identified (patient 8). Diagnosis of HIV was made at 20 weeks gestation and ARV medications initiated at 24 weeks, consistent with European and British HIV Association (BHIVA) guidelines. 11 Despite a delivery viral load of 53 copies per mL 15 and rupture of membranes for 3 hours, HIV-RNA was detected in the infant sample obtained on day 42 of life. Although this is just 1 case, it raises the question as to the most appropriate timing for initiation of ART. Some experts believe that in utero transmission is likely to occur in the second trimester, 16, 17 and thus, initiation of maternal ARV medications prior to 20 weeks might be preferable.
Conclusion
The HIV program in Ireland to minimize MTCT is a great success, with a vertical transmission rate of <1.5%. A 7-year audit of the program detected 12 infected infants. Identifiable risk factors for transmission were found in 11. The arrival of immigrant women late in gestation effectively precluded earlier intervention for them. Locally modifiable risk factors or missed opportunities for prevention were identified and included failure to communicate the benefits of testing, late initiation of ARV medications, poor adherence, and lack of routine testing at delivery. These data can be used to target further interventions to reduce residual transmission. This study highlights the potential role of rapid HIV testing at delivery. The benefits of antenatal testing should be well communicated and understood fully by women. Public health campaigns to encourage preconceptive testing and early presentation to antenatal services are vital and must be inclusive of vulnerable migrant groups. Their critical importance must not be allowed to slip from the public consciousness.
